Strong second quarter, positive project development continues
April – June
• Net revenues increased with 33 percent, and amounted to SEK 404.2 M (304.8). Net profit increased and was SEK 59.8 M (7.1). Earnings per share were SEK 1.31 (0.15). The increase is mainly due to the strong development of the ReFacto® manufacturing revenues
• Cash flow from operations improved the second quarter, and was SEK -16.4 M (-47.2)
• The A2A project, which is based on an entirely new principle for the treatment of neuropathic pain, entered phase II
• Supplementary clinical studies have started on Exinalda™ for the treatment of patients with fat malabsorption due to pancreatic insufficiency
• Martin Nicklasson was appointed as the new CEO effective May 14, 2007

January – June
• Net revenues were 7 percent higher than the same period the previous year and amounted to SEK 757.1 M (708.1). Net profit improved by 11 percent, and was SEK 103.9 M (93.4), earnings per share were SEK 2.28...